Products
Taliglucerase alfa is commercially available as an infusion preparation in some countries (Elelyso). It has not yet been registered in many countries.
Structure and properties
Taliglucerase alfa is an enzyme and an analog of natural glucocerebrosidase, from which it differs in several amino acids. Glycosylation with mannose results in the uptake of taliglucerase alfa predominantly into macrophages.
Effects
Taliglucerase alfa (ATC A16AB11) is an analog of the enzyme beta-glucocerebrosidase. This enzyme hydrolyzes glucocerebroside into glucose and ceramide. Gaucher disease is characterized by a deficiency of this lysosomal enzyme. This leads to accumulation of glucocerebroside in cells, mainly in macrophages.
Indications
For long-term treatment of patients with Gaucher disease type 1.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion every two weeks.
Contraindications
Taliglucerase alfa is contraindicated in cases of hypersensitivity. For complete precautions, see the drug label.
Interactions
There are no known drug-drug interactions.
Adverse effects
The most common possible adverse effects include headache, joint pain, fatigue, nausea, dizziness, abdominal pain, pruritus, flushing, vomiting, and urticaria.
